Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GCK | P35557 | 11/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6077217 | 0.80 | CYP2C19 (0.42) | HPGDKMT2AALDH1A1MEN1CYP3A4 | |
| SCHEMBL7201687 | 0.78 | MTNR1A (0.45) | — | |
| SCHEMBL6075940 | 0.77 | MTNR1A (0.36) | HPGDKMT2AALDH1A1MEN1GCK | |
| SCHEMBL7203251 | 0.66 | MTNR1A (0.43) | SMN1; SMN2 | |
| SCHEMBL6076237 | 0.62 | MEN1 (0.38) | KMT2AALDH1A1MEN1CYP2C19L3MBTL1 | |
| SCHEMBL1690435 | 0.61 | HPGD (0.68) | HPGDKMT2AALDH1A1MEN1CYP3A4 | |
| SCHEMBL8620106 | 0.60 | HPGD (0.62) | HPGDKMT2AALDH1A1MEN1RAB9A | |
| SCHEMBL14753610 | 0.58 | CYP3A4 (0.50) | HPGDKMT2AMEN1CYP3A4CYP2C19 | |
| Butyric Acid SCHEMBL15845048 | 0.57 | ALDH1A1 (0.61) | HPGDKMT2AALDH1A1MEN1RAB9A | |
| Methyl Alcohol SCHEMBL11273876 | 0.57 | L3MBTL1 (0.66) | HPGDKMT2AALDH1A1MEN1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7126012-B2 | Substituted cyclic compounds | LES LABORATOIRES SERVIER (FR) | 2006-10-24 | — | — | US | disclosed |
| US-7115752-B2 | Substituted cyclic compounds | LES LABORATOIRES SERVIER (FR) | 2006-10-03 | — | — | US | disclosed |
| US-20050124682-A1 | Substituted cyclic compounds | LESIEUR DANIEL (FR) | 2005-06-09 | — | — | US | disclosed |
| US-6872851-B1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LES LABORATORIES SERVIER (FR) | 2005-03-29 | — | — | US | disclosed |
| US-20050059729-A1 | Substituted cyclic compounds | LESIEUR DANIEL (FR) | 2005-03-17 | — | — | US | disclosed |
| EP-1077927-A1 | NOVEL SUBSTITUTED CYCLIC COMPOUNDS, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ADIR ET COMPAGNIE (FR) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999058495-A1 | NOVEL SUBSTITUTED CYCLIC COMPOUNDS, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ADIR ET COMPAGNIE (FR) | 1999-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059729-A1 | Substituted cyclic compounds | CCNY, CCNT2, TECR | HPGD 2419/4885KMT2A 1322/4885ALDH1A1 1013/4885 |
| US-20050124682-A1 | Substituted cyclic compounds | CCNY, CCNT2, TECR | HPGD 2419/4885KMT2A 1322/4885ALDH1A1 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.